Shares of medical device company DexCom (NASDAQ:DXCM) fell 14.8% in the afternoon session after the company reported underwhelming earnings. The company's revenue grew over 21% year-on-year to $1.21 ...

DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...

New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. MONTREAL ...

Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or ...

Two years ago, Eli Lilly started working with Dexcom to integrate continuous glucose monitoring (CGM) into its insulin delivery devices, and it has now firmed up the alliance. Lilly has taken a ...

For the quarter ended September 2025, DexCom (DXCM) reported revenue of $1.21 billion, up 21.6% over the same period last year. EPS came in at $0.61, compared to $0.45 in the year-ago quarter. The ...

(Reuters) -Dexcom shares tumbled 12% in premarket trading on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations. Shares ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title, registration ...

G6 Materials Corp., through its subsidiaries, develops, manufactures, and sells proprietary products based on graphene and other materials. It offers air purification materials; general purpose, ...

DexCom may be a major player in the market for continuous glucose monitors, but that doesn’t means it’s shielded from concerns over slower-than-expected growth.